Aim: To investigate the metabolic effects of atypical antipsychotics with or without sodium valproate (VPA) supplementation
Methods: The anthropometrics and metabolic markers were reviewed in 132 Japanese psychotic patients treated with olanzapine, paliperidone, or aripiprazole. The outcome values and triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratios reflecting insulin resistance were compared at baseline and at 3 and 6 months in VPA-non-using (-VPA) patients and VPA-using (+VPA) patients for each atypical antipsychotic.
Results: There were significant increases relative to baseline in body mass index (BMI) at 6 months in olanzapine/-VPA patients, and higher TG levels at 6 months in olanzapine/-VPA patients, olanzapine/+ VPA patients, and paliperidone/-VPA patients. The TG/HDL-C ratio at 6 months was significantly higher in olanzapine/+VPA patients and olanzapine/-VPA patients. Aripiprazole had no significant effects on these markers irrespective of whether or not VPA was used.
Conclusion: Sodium valproate may produce different metabolic effects on body weight, lipid levels, and insulin resistance when combined with various atypical antipsychotics.
2013 The Japanese Society of Clinical Neuropsychopharmacology